Valeant Pharma Settles SEC Accounting Probe For $45M

Law360 (July 31, 2020, 8:51 PM EDT) -- Bausch Health agreed to pay the U.S. Securities and Exchange Commission $45 million on Friday to settle allegations of accounting fraud dating back to when the company was known as Valeant Pharmaceuticals, while three former executives agreed to fines.

In a settlement containing no admission of wrongdoing, the company shed allegations that it had failed to tell investors in 2014 about its relationship with Philidor Rx Services LLC, a mail-order pharmacy that Valeant eventually optioned for purchase, even while Philidor was a major driver of Valeant's sales growth.

The settlement also resolves liability over $110 million in revenue from a price...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!